Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

[1]  G. Thomas,et al.  GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients , 2016, Oncotarget.

[2]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Alain Viari,et al.  A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers , 2016, Nature Communications.

[4]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[5]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[6]  M. Espié,et al.  Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Baselga,et al.  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.

[8]  P. Austin,et al.  The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study , 2014, Statistical methods in medical research.

[9]  H. Joensuu.  Duration of adjuvant trastuzumab: shorter beats longer , 2013, The Lancet.

[10]  M. Dowsett,et al.  2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial , 2013, The Lancet.

[11]  M. Espié,et al.  6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[12]  S. Cannistra,et al.  Evaluation of treatment benefit in Journal of Clinical Oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Barni,et al.  Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better , 2012, Medical Oncology.

[14]  E. Perez,et al.  Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[16]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Zhen-zhou Shen,et al.  Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials , 2011, PloS one.

[18]  R. Gelber,et al.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.

[19]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[20]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[21]  J. Machiels,et al.  Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gelber,et al.  Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[24]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[25]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.